Evotec posts 50% growth with a big year in sight

German contract researcher Evotec grew its revenue by 50% in the first 9 months of 2015, executing its hybrid model and expanding its list of Big Pharma partners.

The company booked €88.2 million ($94.6 million) in the first three quarters. EVT Execute, Evotec's CRO division, grew 52% to €93.4 million ($100.1 million), while EVT Innovate, which outlicenses proprietary treatments, rose 34% to €14.3 million ($15.3 million). Intersegment eliminations, in which Execute sells services to Innovate, totaled €13.2 million ($14.2 million), accounting for the net revenue difference.

Evotec's net income came in at €10.7 million ($11.5 million) for the first 9 months, besting the €8 million ($8.6 million) loss it posted in the same period last year.

Now the company is expecting full-year revenue to grow 45% over 2014. Evotec has raised its expectations three times this year, starting out with a 10% growth projection that moved to 20%, 35% and now 45%.

Fueling that optimism is a string of partnerships with the likes of Sanofi ($SNY), Roche ($RHHBY), Johnson & Johnson ($JNJ) and, most recently, Pfizer ($PFE). Evotec has also entered into R&D deals with research foundations and academic institutes, lending its development expertise and compound library out in exchange for service fees.

- read the results

Suggested Articles

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.

Aetion has raised $50 million so far, and it plans to enhance its platform to support more complex therapeutic areas and expand its team.

Charles River partners with PathoQuest to offer clients NGS solutions for biologics viral contamination testing and cell-line genetic characterization.